The stock of CSL Limited (ASX:CSL) gapped up by $0.25 today and has $144.67 target or 45.00% above today’s $99.77 share price. The 8 months technical chart setup indicates low risk for the $45.49B company. The gap was reported on Nov, 7 by Barchart.com. If the $144.67 price target is reached, the company will be worth $20.47 billion more.
Gaps up are useful for using as a support level and to some extent as a tradeable event. If investors already hold the stock and experience a price gap up, then its usually a good idea to hold the stock for a stronger up move. Back-tests of these patterns indicate that two-thirds of the times the stock performance improves after the gap. The area gaps close 89% of the time, the breakaway gaps, 2%, the continuation gaps 4% and the exhaustion gaps 61%. The stock increased 1.13% or $1.11 on November 7, hitting $99.77. About 1.05 million shares traded hands or 15.46% up from the average. CSL Limited (ASX:CSL) has declined 0.42% since April 11, 2016 and is downtrending. It has underperformed by 2.38% the S&P500.
More notable recent CSL Limited (ASX:CSL) news were published by: Fool.com.Au which released: “CSL Limited is below $100: Time to buy shares?” on October 31, 2016, also Fool.com.Au with their article: “Are CSL Limited shares cheap today?” published on September 07, 2016, Fool.com.Au published: “3 reasons to buy CSL Limited” on October 06, 2016. More interesting news about CSL Limited (ASX:CSL) were released by: Fool.com.Au and their article: “Will CSL Limited return to $120 per share?” published on September 28, 2016 as well as Fool.com.Au‘s news article titled: “Is CSL Limited headed back to $120?” with publication date: September 12, 2016.
CSL Limited is a biotherapeutics company that develops and delivers biotherapies. The company has a market cap of $45.49 billion. The Company’s principal activities are research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. It has a 28.45 P/E ratio. The Company’s divisions include CSL Behring, Seqirus and CSL Intellectual Property.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.